Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | CNR2 | P34972 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6022153 | 0.95 | RXFP1 (0.51) | RXFP1KDM4EPKMMAPK1CNR2 | |
| SCHEMBL6022348 | 0.92 | RXFP1 (0.53) | RXFP1KDM4EPKMMAPK1PTPN1 | |
| SCHEMBL6022256 | 0.84 | MAPK1 (0.48) | RXFP1KDM4EPKMMAPK1KMT2A | |
| SCHEMBL6022392 | 0.83 | POLB (0.49) | KDM4EPKMMAPK1POLB | |
| SCHEMBL6022142 | 0.82 | NR3C1 (0.55) | PTPN1CNR2KMT2AMEN1CNR1 | |
| SCHEMBL6023077 | 0.79 | KDM4E (0.61) | RXFP1KDM4EPKMKMT2APOLB | |
| SCHEMBL6022484 | 0.78 | ALDH1A1 (0.62) | KDM4EPKMMAPK1POLB | |
| SCHEMBL6022647 | 0.78 | KDM4E (0.51) | RXFP1KDM4EKMT2APOLBMEN1 | |
| SCHEMBL6022155 | 0.77 | ALDH1A1 (0.54) | KDM4EPKMMAPK1POLB | |
| SCHEMBL6022431 | 0.76 | BRD1 (0.61) | PKMMAPK1KMT2ATAS2R14MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7009052-B2 | Sulfonamide derivatives | WARNER LAMBERT COMPANY LLC (US) | 2006-03-07 | — | — | US | claimed |
| US-20050004367-A1 | Sulfonamide derivatives | DU DANIEL Y (US) | 2005-01-06 | — | — | US | claimed |
| US-7009052-B2 | Sulfonamide derivatives | WARNER LAMBERT COMPANY LLC (US) | 2006-03-07 | — | — | US | disclosed |
| US-20050004367-A1 | Sulfonamide derivatives | DU DANIEL Y (US) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004367-A1 | Sulfonamide derivatives | AR, SULT2A1, SHBG | RXFP1 1706/4885KDM4E 1224/4885PKM 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.